A FORMULATION INTENDED FOR TREATMENT OF PARKINSON'S DISEASE
Creators: name: Alkoclar, Erdal Can
Publisher: name: Zenodo
Year: 2020
Subjects: Dopaminergic D2 Receptors Tyrosine Hydroxylase

description: The present invention herewith is related to a formulation developed for symptomatic treatment of Parkinson’s Disease <strong>Background of the Related Technology</strong> Today it is known that Parkinson’s disease is a nervous system disease related to an abnormality of the gray substance (substantia grisea) at lower part of the brain. It is generally a middle age disease. Its name comes from James Parkinson, who has described the disease for the first time in 1817 as paralysis agitans. The disease is observed at a rate of one out of thousand people, and is a chronic progressive disease with no treatment. The invention presented herewith with no “WO 1999/049852", with title "Transdermal Therapy System that Includes D2-Agonist for Treatment of Parkinson’s Syndrome and Methods for Manufacturing it" and under classification number “A61K 9/70", which is related to a transdermal therapy system that has a self-adhesive matrix layer containing (-)-5,6,7,8-Tetrahydro-6-[propyl[2-(2-thienyl)-ethyl] amino]-1-naphthol at an active quantity, which adheres to a hind layer that does not react to the materials contained by the matrix and the system which has a protective foil that has to be removed before using, is characterized by being based on an acrylate or silicon based non-aqueous polymer adhesive system with a solubility of %&gt;= 5 g/g for (-)-5,6,7,8-tetrahydro-6-[propyl [2-2(-thienyl)-ethyl] amino] -1- naphthol and having a matrix that is considerably purified from inorganic silicate particles. Again the invention presented herewith with no "WO 2000/016777", with title "Medicine for treatment of Parkinson’s Disease, ADHD and Microadenoma” and under classification number "A61K 31/505", is related to compositions known as bis-azo bicyclic compounds and having formula (I) where some pirido [1,2-a]- pyrazine derivatives are used for treatment of hyperactivity related to attention deficit in Parkinson’s Disease in mammals and related compositions thereof. Again the invention presented herewith with no "EP1835924B1", with title "Treatment of Parkinson’s Disease and Related Deficiencies by Using Post Natal Stem Cells” and under classification number "A61K 35/44", is related to cell based and regenerative treatments targeting individuals suffering from neurodegenerative disorders developing in the substantia nigra or striatum region. Again the invention presented herewith with no “EP2344471B1", with title "7-piperidinoalkyl-3,4-dihydroquinolon derivative" and under classification number "C07D 401/06", is related to providing a new compound that is useful in prevention or treatment of depression, anxiety disorders (e.g., generalized anxiety disorder, post-traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorder, stress, sleep disorder, attack, memory functional disorder, cognitive disorder, dementia, amnesia, delirium, mental deterioration, obesity, eating disturbance, appetite disorders, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular disease, high blood pressure, dyslipedimia, cardiac infarct, movement disorder (e.g. Parkinson’s Disease, epilepsy, convulsions, tremors), drug abuse disorder, drug addiction and sexual function disorders, based on antagonistic effect on a melanin concentrating hormone receptor (MCH receptor), as well as a pharmaceutically acceptable salt or hydrate of the compound thereof. The SOLUTION is a compound represented with formula (I), a pharmaceutically acceptable salt or a hydrate of the compound. To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation intended for treatment of Parkinson’s Disease. <strong>Objective of the Invention</strong> To overcome the disadvantages referred in the Background of the Related Technology, One objective of the present invention is to enhance BDNF . One other objective of the invention is to stimulate production of natural dopamine. One other objective of the invention is to enhance D1 and D2 receptor sensitivity. One other objective of the invention is to enhance nervous growth factor expression. One other objective of the invention is to enhance igf-1 expression. One other objective of the invention is suppression of prolactin secretion. The present invention, which is aimed to achieve the above-mentioned advantages, is intended for symptomatic treatment of Parkinson’s Disease and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one, 2,3-bis(6-oxoethyl)-4-0-dioxin, 3,5-methoxy-stigmast-6-ene-phenyl-4-one, 11-oxo-alphamethyldioxin, 3,5-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one, 7-bis(6-oxoethyl)-4-0-dioxin, 3,5-methoxy-stigmast-6-ene-phenyl-4-one. Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith. <strong>Detailed Description of the Invention</strong> The present invention is related to a formulation intended for symptomatic treatment of Parkinson’s Disease. The referred formulation, enhances BDNF expression, stimulates production of natural dopamine, enhances D1 and D2 receptor sensitivity, enhances expression of nerve growth factor, enhances igf-1 expression and suppresses prolactin secretion. Formulation related to the present invention contains; 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one, 2,3-bis(6-oxoethyl)-4-0-dioxin, 3,5-methoxy-stig-mast-6-ene-phenyl-4-one, 11-oxo-alphamethyldioxin, 3,5-bis(2-dimethyl)-6-O-stig-mast-4-ene-coumaroil-3-one, 7-bis(6-oxoethyl)-4-0-dioxin, 3,5-methoxy-stigmast-6-ene-phenyl-4-one. The referred formulation is formed by mixing the above-mentioned components at below percentages by weight; 3-8% of 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one; 11-4% of 2,3-bis(6-oxoethyl)-4-0-dioxin; 16-20% of 3,5-methoxy-stigmast-6-ene-phenyl-4-one; 10-12% of 11-oxo-alphamethyldioxin; 12-18% of 3,5-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one; 33-11% of 7-bis(6-oxoethyl)-4-0-dioxin; 15-29% of 3,5-methoxy-stigmast-6-ene-phenyl-4-one. Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof. The present invention at the same time is related to using the above-referred formulation for symptomatic treatment of Parkinson’s Disease and manufacturing it for such purpose.